Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid plus hydroquinone versus hydroquinone alone for melasma
ACTRN12626000420347Phase 4Recruiting
- Sponsor
- PNS Shifa
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tranexamic acid and hydroquinone in melasma (2 arms), sponsored by PNS Shifa. Primary endpoints: Clinical change in melasma lesions and Patient satisfaction score. Started Jan 2026; status: recruiting.
02
Drugs
tranexamic acidhydroquinone
03
Conditions
melasma
Beyond the preview
Go deeper on ACTRN12626000420347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000420347.